Skip to content
Screener

Gilead Sciences GILD Q2 2026 earnings

Reported August 3, 2026 · After market close

Revenue$7.8BBeat by $404.3M
EPS-$6.75Beat by $0.50
Revenue estimate$7.4B
EPS estimate-$7.25
“Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026. We also made significant clinical progress with three FDA approvals and three positive Phase 3 updates. We look forward to delivering on our many opportunities in the second half of the year including another two potential launches in oncology and HIV.”
Daniel O'Day

Next report

Oct 29, 2026 (In 3 weeks)
Revenue estimate$7.8B
EPS estimate$2.12

Financials

Q2 2026

Income statement

See full
Revenue$7.8B+10.2%
Gross profit$6.2B+11.5%
Operating income-$10.4B-520%
Net income-$10.5B-636%
EPS (diluted)-$8.45-642%

Balance sheet

See full
Cash & equivalents$3.2B-38.2%
Total debt$26.2B+5.2%
Total equity$11.8B-39.9%
Total assets$49.4B-11.4%

Cash flow

See full
Operating cash flow$3.6B+332%
CapEx$140.0M+30.8%
Free cash flow$3.4B+377%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$182.89B+33.3%
Enterprise value$205.96B+33.1%
P/S6×+1.3×

Profitability

See full
Gross margin79.6%+1.1pp
Operating margin-8.2%-36.1pp
Net margin-10.6%-32.5pp
FCF margin42.5%+10.0pp

Returns & leverage

See full
Return on equity-20.6%-53.8pp
Debt / equity2.2×+1.0×
Current ratio1.3×0.0×

Segments

By product

See full
Biktarvy$3.8B+6.9%
Descovy$967.0M+48.1%
Trodelvy$457.0M+25.5%
Yescarta$346.0M-12.0%
Sofosbuvir/Velpatasvir$303.0M-11.4%

By geography

See full
Europe$1.3B+11.4%
Rest of World$876.0M+4.0%

FAQ

When did Gilead Sciences report Q2 2026 earnings?
Gilead Sciences (GILD) reported Q2 2026 earnings on August 3, 2026 after market close.
What were Gilead Sciences's Q2 2026 revenue and EPS?
Gilead Sciences reported revenue of $7.8B and eps of $-6.75 for Q2 2026.
Did Gilead Sciences beat estimates in Q2 2026?
Revenue beat the consensus estimate of $7.4B by $404.3M. EPS beat the consensus estimate of $-7.25 by $0.50.
How did Gilead Sciences's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 10.2% from $7.1B a year earlier.
Where can I find Gilead Sciences's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000882095-26-000028) and the 10-Q periodic report (0000882095-26-000031) directly on SEC EDGAR. The filing index links above go to sec.gov.